Onco Actu du 11 octobre 2019

	3.1.1 PRÉVENTION - TABAC - E-CIGS
Vaping Illnesses Climb Upward, Nearing 1,300 With 29 Deaths [NY Times] The ages of those who died range from 17 years to 75 years, with a median of 49. The exact cause of the illness is still unknown. Many of those who became ill had vaped THC, some had used both THC and nicotine, and others report vaping only nicotine.
U.S. vaping-related deaths rise to 26, illnesses to 1,299 [Reuters] Investigators have not linked the cases to any specific product or compound, but have pointed to vaping oils containing THC, the psychoactive ingredient in marijuana, as being especially risky.
	4.9 DÉP., DIAG. & PRONO. - SEIN
It’s Ok to Opt Out of Mammograms [The Last Word On Nothing] None of the mammography studies we have is perfect, but in absolute numbers, there’s no question that far more women are harmed than helped by mammograms. Yet because the comparison is essentially apples to oranges (unnecessary treatments versus a life saved, for instance), deciding whether the harms are outweighed by the benefits comes down to a values judgement, not a math problem.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Resisting Protein Degradation: The Cells Fight Back [In The Pipeline] This is an area of research that we can expect to see more of as we continue to make more degraders and send more of them into the clinic: you not only want to target proteins that are important in some particular disease, but you want to make sure that your targeted protein is optimally degradable by the system you’re choosing.
	5.10 TRAITEMENTS - ESSAIS
Monoclonal Antibody Treatment Combined with Induction Chemotherapy Yielded Promising Outcomes in High-Risk Neuroblastoma [AACR] The study enrolled 43 patients, 19 years or younger, with newly diagnosed high-risk neuroblastoma. Patients received six courses of induction chemotherapy in combination with hu14.18K322A, followed by immune-boosting factors.
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
New batch of treatment decisions for NHS Scotland [Cancer Research UK] Yescarta isn’t the only immunotherapy recommended for NHS use. A new combination treatment for non small cell lung cancer will also be available to some patients in Scotland. The remaining decisions included drugs for breast and prostate cancer.
	5.2.3 PHARMA - ÉCONOMIE
Wall Street trims cancer drug developer BioNTech's unicorn valuation [EndPoints] After ADC Therapeutics rescinded its plans earlier this month for a public listing — citing an adverse environment — Germany’s BioNTech on Thursday unveiled its downsized IPO, raising about $100 million less than the $251 million that it had previously envisioned.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
N-of-1 Trials: FDA Plots Path to Regulation [RAPS] The US Food and Drug Administration (FDA) is taking notice of a unique and recent phenomenon where physicians and specialists can create a tailored treatment to help or even cure an individual patient with a rare genetic mutation that could prove fatal.
	5.4 TRAITEMENTS - ECONOMIE
Another treatment option for ovarian cancer approved for the Cancer Drugs Fund [NICE] Rucaparib can now be offered to women with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy. Taken as a tablet, twice daily, it slows the progression of cancer by preventing cancer cells repairing so slowing down the tumour’s growth.
	5.5 ASCO
Researchers Identify Genetic Markers for Response to Radiation Therapy and Prediction of Recurrence [ASCO] The findings come from two studies that will be presented at ASCO Breakthrough: A Global Summit for Oncology Innovators, taking place October 11-13, 2019 in Bangkok.
New Technologies Offer the Possibility of Identifying Cancer from a Single Blood Draw [ASCO] The data presented at the ASCO Breakthrough meeting include the validation analysis from a pre-planned sub-study of the Circulating Cell-free Genome Atlas (CCGA) study. The study was funded by GRAIL, Inc.
	6.1 OBSERVATION
Quarter of women with incurable breast cancer sees GP at least three times before diagnosis [The Telegraph] Professor Helen Stokes-Lampard, chairman of the Royal College of GPs, said doctors were highly trained to spot signs of recurrence but that some symptoms “are very difficult to interpret”.
'Unacceptable' delays in diagnosing secondary breast cancer [BBC News] One in four patients with secondary breast cancer had to visit their GP three or more times before they got a diagnosis, a survey suggests.
	6.13 SOINS PALLIATIFS
Is precision medicine ignoring people dying of cancer? [Cancer World] While we’re pouring resources into learning what keeps cancer cells alive, with the aim of blocking their supply lines, there is next to no interest in the molecular pathways that end up choking the life out of cancer patients, or in the biology behind the longer and better lives that palliative care can offer.
	6.6 PUBLICATIONS
In bid to boost transparency, bioRxiv begins posting peer reviews next to preprints [Science] A related experiment will provide new test of “portable” peer reviews.
Predicting translational progress in biomedical research [PLOS Biology] We found that distinct knowledge flow trajectories are linked to papers that either succeed or fail to influence clinical research. Translational progress in biomedicine can therefore be assessed and predicted in real time based on information conveyed by the scientific community’s early reaction to a paper.
	6.7 DMP, BIG DATA & APPLIS
Researchers Find 15% of Trials Could be Replicated Using Real World Data [RAPS] To conduct the study, the authors reviewed 220 clinical trials conducted in the US that were published in the top seven medical journals in 2017 and determined whether RWD obtained from insurance claims and electronic health records (EHRs) contained the information necessary to replicate the studies